The Senate health committee will finally train its spotlight on the high cost of prescription drugs in a highly anticipated public hearing Tuesday, the first major congressional examination of the issue since President Trump took office buoyed in part by his promises to lower prices.

Trump famously accused pharmaceutical companies of “getting away with murder” in January — but don’t expect the panel to be a slugfest.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • In most cases, talk is cheap. But, when it comes to congress, through no fault of their own, they may well wind up giving away most if not all of the savings to someone other than their constituents by the time anything gets done.

    Its ironic (and heartbreaking) that a country with so much innovation and so many resources cannot seem to identify and fix these or other problems.

  • Dream on! Legislators are not going to cut their food supply chain that lets them get elected.

    Many things have to happen to get there. No one wants to kill the golden goose.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy